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CHARACTERIZING LOST PRODUCTIVITY AND DIRECT AND INDIRECT 
COSTS OF RHEUMATOID ARTHRITIS—A LARGE, SELF-INSURED 
EMPLOYER’S PERSPECTIVE
Naim A1, Bunn W2, Allen H3
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Navistar, Inc, Warrenville, IL, 
USA, 3Harris Allen Group, LLC, Brookline, MA, USA
OBJECTIVES: To characterize burden of illness, health care resource utilization, and 
direct and indirect costs of select auto-immune disorders. METHODS: A retrospective 
cross-sectional analysis was performed using data from Navistar, Inc. This integrated 
dataset included health care claims (medical and pharmacy), absenteeism, workers 
compensation, short and long term disability. Individuals were identiﬁed as having 
RA based on ICD-9 classiﬁcation code 714.xx. Active employees, their dependents, 
and retirees were included in the study. Indirect costs were calculated from absenteeism 
and short-term disability days using aggregate payroll data. RESULTS: 1,344 RA 
sufferers were identiﬁed among the total sample (n = 65,000). Among the RA sufferers, 
53% were retirees, 42% were dependents and 5% were active employees. 60% were 
over the age of 50 years and more than two-thirds (70%) were females. A high rate 
of comorbidities was also observed, with 40% having more than three comorbid 
conditions. The top three comorbid conditions were chronic obstructive pulmonary 
disorder, (COPD) (23%), congestive heart failure (CHF) (19%), and vascular disease 
(18%). RA sufferers used health care services at a high annual rate (ambulatory/physi-
cian ofﬁce visits = 9.9, emergency visits = 1.8). Subsequently, the annual total direct 
costs of RA were also high at $8461 per patient. Among active employees, a high rate 
of short-term disability was observed (mean = 13.8%), whereas absence days were 
observed at a mean of 4.2 days per annum. Annual total indirect costs were calculated 
to be $2963 per employee, including absenteeism ($710), short-term disability 
($1015), workers compensation ($757), and long-term disability ($340). CONCLU-
SIONS: RA presents a signiﬁcant total health care cost burden for employers. Employ-
ers should include dependents and retirees to determine the full impact of RA on total 
costs. Employees with RA miss more work days, are less productive, and tend to utilize 
disability. Prospective studies are needed to determine employee presenteeism to 
comprehensively measure productivity loss.
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COMPARISON OF MEDICAL RESOURCE USE AND COSTS ASSOCIATED 
WITH FIBROMYALGIA IN FRANCE, GERMANY AND THE UNITED 
STATES
Knight T1, Schaefer C1, Chandran A2, Zlateva G2, Goldenberg D3, Winkelmann A4, 
Perrot S5
1Covance, Gaithersburg, MD, USA, 2Pﬁzer Inc., New York, NY, USA, 3Newton-Wellesley 
Hospital, Newton, MA, USA, 4University Hospital Munich, Munich, Germany, 5Hospital Hotel 
Dieu, Paris, France
OBJECTIVES: Fibromyalgia (FM) is a chronic disorder characterized by persistent, 
widespread pain among other symptoms. This study compares FM practice patterns 
and costs across the US and Europe in routine clinical practice. METHODS: Data 
from cross-sectional, observational studies of FM subjects 18–65 years of age in the 
US and Europe (France and Germany) were analyzed. Medical resource use (MRU) 
related costs were abstracted from retrospective chart review; patient out-of-pocket 
costs and lost productivity were collected via subject self-report. Direct and indirect 
costs, related to absenteeism and disability, due to FM were calculated using standard 
costing algorithms and reported in 2009 US dollars. Descriptive statistics on select 
variables and direct and indirect medical costs to society are reported. RESULTS: 
A total of 442 subjects (203 US, 70 France, 169 Germany) were analyzed. The U.S., 
French, and German mean (SD) age was 47.9 (10.9), 51.2 (9.47), and 49.2 (9.80), 
respectively. Approximately 95% of the U.S. subjects were female compared to 83% 
in France and 80% in Germany. Approximately 40% of U.S. and French subjects 
and 44% of German subjects were employed either full- or part-time. More than 
27% of U.S. patients were disabled, compared to 11% and 3% in France and 
Germany, respectively. Approximately 6% of U.S. subjects were retired compared 
to 24% in France and 10% in Germany. The mean (SD) annual direct costs per 
subject for FM were $7974 (7341) in the U.S., $924 (862) in France and $2234 
(2641) in Germany. The mean (SD) annual indirect costs per subject in the U.S. 
were $10,697 (20,463) compared to $9,819 (18,242) in France and $7,898 (15,822) 
in Germany. CONCLUSIONS: Total direct costs contribute more to the overall US 
cost in comparison to France and Germany, but total indirect costs due to absentee-
ism and disability proportionally contribute more in these countries compared to 
the U.S.
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ANALYSIS OF DIAGNOSES RELATED GROUP NUMBER 234— 
OTHER MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE—
OPERATING ROOM PROCEDURES
Stallard R
University of Louisville, Louisville, KY, USA
OBJECTIVES: Analyze the data for statistically signiﬁcant trends in comparison 
between DRG 234 and the general population. METHODS: An experimental dataset 
is created by combining the data pertaining to DRG 234 with an equally sized random 
sample (excluding DRG 234) dataset, resulting in an experimental dataset of 5558 
patients’ entries. These data come from the 2007 Healthcare Cost and Utilization 
Project (HCUP) Kids Inpatient Database (KID). Using commercial Statistical Analysis 
Software (SAS Enterprise Guide) and code native to SAS, various analysis techniques 
will be used to describe statistical trends in these data. RESULTS: A one-way fre-
quency analysis shows that DRG 234 has a disproportionately high occurrence in the 
Hispanic population, 18.58 % in the control group compared to 12.76% in the 
experimental group. A frequency count also shows that these diagnoses most often 
occur before the ﬁrst birthday—this is a result of many ICD 9 codes being congenital 
muscoskeletal disorders categorized under DRG 234. The diagnoses and procedures 
grouped under DRG 234 tend to result in a shorter stay but are more costly in terms 
of total charges. Linear models suggest that the total charges to Asian or Paciﬁc 
Islander patients tend to be higher than the other racial categories’ mean total charges. 
CONCLUSIONS: It is suggested that further study is completed in analyzing the 
relationship between age, race, diagnoses and procedures to determine a deﬁnite 
relationship between those variables. Particular subjects that may be worthwhile to 
investigate are: The percentage of congenital conditions in Hispanic infants compared 
to the rest of the population, the particular diagnoses and procedure codes and their 
typical costs and occurrences for the different racial categories, and an analysis of how 
the various procedure and diagnosis codes being categorized in an ‘other’ group might 
skew the data, thereby introducing difﬁculties in the modeling process.
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ESTIMATION OF COSTS OF HEALTH CARE FOR PEOPLE WITH 
RHEUMATOID ARTHRITIS FOR VARYING DEGREES OF DISABILITY AS 
MEASURED BY THE HEALTH ASSESSMENT QUESTIONNAIRE IN THE 
UNITED KINGDOM
Currie CJ1, Poole CD2, Singh A3, Reynolds A4
1Cardiff University, Cardiff, Wales, UK, 2Pharmatelligence, Cardiff, UK, 3Pﬁzer, Philadelphia, 
PA, USA, 4Pﬁzer, Maidenhead, UK
OBJECTIVES: Rheumatoid arthritis (RA) confers both signiﬁcant short- and long-
term disability, and substantial background health care costs, yet cost data are scarce. 
We modeled disability in RA using covariates also available in routine, primary care 
data from which total health care cost were estimated. METHODS: In modeling dis-
ability, biologic-naïve RA cases from the UK biologics register were selected. General 
Linear Modeling (GLM) was used to predict HAQ score from demographics, co-
morbidity, polypharmacy, RA duration, BMI, smoking status and disease activity. 
Health care costs were estimated from similar incident cases with > = 1 year’s observa-
tion selected from the THIN database. Annual costs included prescriptions, consulta-
tions, and investigations from primary care and hospital episodes. An alternatve 
generalised linear model assumed a Poisson distribution, and a log-link explored the 
association between health care costs and predicted HAQ. RESULTS: Disability was 
modeled using 3,924 cases, of whom 75% were female with an average age of 58 
years (sd 14) and an average baseline HAQ of 1.80 (sd 0.72). The optimal HAQ model 
included gender, RA duration, number prior DMARDs, number of current non-
DMARD drugs, logCRP, smoking status and stroke history. The r2 value was 0.27, 
while mean prediction error was 0.15 (sd 0.30). Costs were assessed in 3,378 cases 
with similar gender balance but slightly older (mean 64 years). Their predicted HAQ 
scores ranged from 0.48 to 3.00, with a mean of 1.60 (sd 0.40). The mean total cost 
of care in this population was £1,960 per annum (sd, £1,864), with prescriptions the 
largest component (43%), followed by outpatient attendances (18%), GP consulta-
tions (16%), and hospital admissions (13%). Predicted total costs (GBP2007) ranging 
from £650 to £10,017 were calculated from EXP^(5.949+(Age*0.002)+(pHAQ*0.67
5)+(Age*pHAQ*0.003)). CONCLUSIONS: Total health care costs for RA patients 
increased exponentially across the range of estimated disability. Exclusion of support-
service costs suggests these values may be conservative.
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RHEUMATOID ARTHRITIS (RA) TREATMENT COSTS AMONG U.S. 
PATIENTS TREATED WITH INFUSED BIOLOGICS
Ogale S1, Henk HJ2
1Genentech, South San Francisco, CA, USA, 2i3 Innovus, Eden Prairie, MN, USA
OBJECTIVES: To determine the real-world, one-year cost of RA treatment for patients 
initiating therapy with an infused biologic from a US commercial payer perspective. 
METHODS: We conducted a retrospective, administrative claims-based analysis of 
RA patients enrolled in a large U.S. managed care plan who initiated an infused RA 
biologic (inﬂiximab, abatacept, rituximab) between January 2, 2006 to January 31, 
2009. Patients ≥18 years of age, with ≥1 diagnosis of RA and continuously enrolled 
in the health plan 6 months prior to and ≥12 months following treatment initiation, 
were included. Patients with diagnoses of non-RA conditions for which the study drugs 
are used were excluded. We assumed that rituximab and abatacept patients had 
received ≥1 anti-TNF agent, and only included inﬂiximab patients who had evidence 
of a prior anti-TNF agent. Generalized linear models with a log link and gamma 
distribution were employed to compare Total RA-related costs (RA medication + 
health care services with diagnosis of RA), RA medication costs (biologics, other 
DMARDs, NSAIDs, corticosteroids) and Index biologic costs (drug + administration), 
among patients treated with each infused biologic, while controlling for demographics, 
co-morbidity score, plan type, index year, and prior RA medications (methotrexate, 
NSAIDS, corticosteroids). RESULTS: A total of 813 patients met the inclusion criteria 
(n = 156 inﬂiximab, n = 418 abatacept, n = 239 rituximab), 82% women, average 
age 52 years (SD = 11.7). During the one-year following treatment initiation adjusted 
costs were as follows: Total RA-related health care costs (Rituximab = $26,783; 
Abatacept = $24,344; Inﬂiximab = $27,053; p = 0.1249), RA medication costs (Ritux-
imab = $19,973; Abatacept = $19,000; Inﬂiximab = $20,763; p = 0.1840), and Index 
biologic costs (Rituximab = $17,638; Abatacept = $16,233; Inﬂiximab = $17,845; p 
= 0.1256). CONCLUSIONS: We did not ﬁnd a difference in one-year RA-medication 
